Trial Profile

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients With Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Narazaciclib (Primary)
Indications Advanced breast cancer; Cancer; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Onconova Therapeutics

02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
05 Dec 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
05 Dec 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com